Atara Biotherapeutics Stock Performance
| ATRA Stock | USD 4.45 0.14 3.05% |
The firm shows a Beta (market volatility) of 1.36, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Atara Biotherapeutics will likely underperform. At this point, Atara Biotherapeutics has a negative expected return of -1.08%. Please make sure to confirm Atara Biotherapeutics' value at risk, rate of daily change, and the relationship between the total risk alpha and kurtosis , to decide if Atara Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Atara Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
Five Day Return (8.44) | Year To Date Return (74.96) | Ten Year Return (98.86) | All Time Return (98.33) |
Last Split Factor 1:25 | Last Split Date 2024-06-20 |
1 | Disposition of tradable shares by Panacea Innovation Ltd of Atara Biotherapeutics at 14.03 subject to Rule 16b-3 | 11/28/2025 |
2 | Can Atara Biotherapeutics Inc. stock sustain revenue momentum - Insider Selling AI Powered Market Trend Analysis - Newser | 12/02/2025 |
3 | Panic Selling Why Atara Biotherapeutics Inc stock could be next big winner - 2025 Buyback Activity Fast Momentum Stock Entry Tips - moha.gov.vn | 12/10/2025 |
4 | Is Atara Biotherapeutics Inc. stock a good choice for value investors - July 2025 Retail Real-Time Volume Analysis Alerts - | 12/18/2025 |
5 | Atara revises tab-cel commercialization milestones with Pierre Fabre - TipRanks | 01/02/2026 |
6 | Disposition of 262 shares by Eric Hyllengren of Atara Biotherapeutics at 255.25 subject to Rule 16b-3 | 01/05/2026 |
7 | Atara Biotherapeutics Shares Down 21.6 percent - Whats Next - MarketBeat | 01/09/2026 |
8 | Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO | 01/12/2026 |
9 | FDA Reversal Sends Atara Biotherapeutics into Tailspin Stock Plummets 67 percent on Second CRL for Tabelecleucel - FinancialContent | 01/14/2026 |
10 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims on Behalf of Investors ofAtara Biotherapeutics, Inc. - ATRA | 01/27/2026 |
11 | INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA | 02/12/2026 |
| Begin Period Cash Flow | 26 M | |
| Total Cashflows From Investing Activities | 8.6 M |
Atara Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 1,310 in Atara Biotherapeutics on November 16, 2025 and sell it today you would lose (865.00) from holding Atara Biotherapeutics or give up 66.03% of portfolio value over 90 days. Atara Biotherapeutics is currently does not generate positive expected returns and assumes 9.8876% risk (volatility on return distribution) over the 90 days horizon. In different words, 88% of stocks are less volatile than Atara, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Atara Biotherapeutics Target Price Odds to finish over Current Price
The tendency of Atara Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.45 | 90 days | 4.45 | about 91.55 |
Based on a normal probability distribution, the odds of Atara Biotherapeutics to move above the current price in 90 days from now is about 91.55 (This Atara Biotherapeutics probability density function shows the probability of Atara Stock to fall within a particular range of prices over 90 days) .
Atara Biotherapeutics Price Density |
| Price |
Predictive Modules for Atara Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Atara Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Atara Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Atara Biotherapeutics is not an exception. The market had few large corrections towards the Atara Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Atara Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Atara Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.93 | |
β | Beta against Dow Jones | 1.36 | |
σ | Overall volatility | 5.27 | |
Ir | Information ratio | -0.09 |
Atara Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Atara Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Atara Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Atara Biotherapeutics generated a negative expected return over the last 90 days | |
| Atara Biotherapeutics has high historical volatility and very poor performance | |
| Atara Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 128.94 M. Net Loss for the year was (85.4 M) with profit before overhead, payroll, taxes, and interest of 71.05 M. | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (68.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Atara Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company shares are held by company insiders | |
| Latest headline from prnewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA |
Atara Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Atara Stock often depends not only on the future outlook of the current and potential Atara Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Atara Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 7.5 M | |
| Cash And Short Term Investments | 42.5 M |
Atara Biotherapeutics Fundamentals Growth
Atara Stock prices reflect investors' perceptions of the future prospects and financial health of Atara Biotherapeutics, and Atara Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Atara Stock performance.
| Return On Equity | -20.15 | ||||
| Return On Asset | 0.31 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | (1.03) % | ||||
| Current Valuation | 35.33 M | ||||
| Shares Outstanding | 7.21 M | ||||
| Price To Earning | (4.50) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 0.21 X | ||||
| Revenue | 128.94 M | ||||
| Gross Profit | 71.05 M | ||||
| EBITDA | (75.75 M) | ||||
| Net Income | (85.4 M) | ||||
| Cash And Equivalents | 331.31 M | ||||
| Cash Per Share | 3.51 X | ||||
| Total Debt | 43.83 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 5.28 X | ||||
| Book Value Per Share | (5.08) X | ||||
| Cash Flow From Operations | (68.72 M) | ||||
| Earnings Per Share | 2.86 X | ||||
| Market Capitalization | 32.09 M | ||||
| Total Asset | 109.1 M | ||||
| Retained Earnings | (2.05 B) | ||||
| Working Capital | (69.68 M) | ||||
| Current Asset | 324.6 M | ||||
| Current Liabilities | 9.71 M | ||||
About Atara Biotherapeutics Performance
By analyzing Atara Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Atara Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Atara Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Atara Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 212.88 | 321.09 | |
| Return On Tangible Assets | (0.70) | (0.74) | |
| Return On Capital Employed | 3.77 | 3.95 | |
| Return On Assets | (0.70) | (0.74) | |
| Return On Equity | 1.01 | 1.60 |
Things to note about Atara Biotherapeutics performance evaluation
Checking the ongoing alerts about Atara Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Atara Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Atara Biotherapeutics generated a negative expected return over the last 90 days | |
| Atara Biotherapeutics has high historical volatility and very poor performance | |
| Atara Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 128.94 M. Net Loss for the year was (85.4 M) with profit before overhead, payroll, taxes, and interest of 71.05 M. | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (68.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Atara Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company shares are held by company insiders | |
| Latest headline from prnewswire.com: INVESTOR ALERT Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA |
- Analyzing Atara Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Atara Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Atara Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Atara Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Atara Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Atara Biotherapeutics' stock. These opinions can provide insight into Atara Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Atara Stock analysis
When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance |